US appeals court to weigh reviving cases over Tylenol and autism

A U.S. appeals court is set to hear arguments to reinstate over 500 lawsuits against Kenvue, the Tylenol manufacturer, alleging a link between the painkiller and autism, after a lower court previously dismissed the cases. Plaintiffs are leveraging a September press conference where former President Donald Trump and health officials linked Tylenol to autism to support their appeal. This legal challenge unfolds as Kimberly-Clark proceeds with its planned $40 billion acquisition of Kenvue, though the merger agreement reportedly specifies that such allegations would not constitute grounds for deal termination. Kenvue continues to assert Tylenol's safety, and a separate lawsuit by the Texas Attorney General recently failed to block Kenvue's dividend payment or modify its marketing.

Analysis

A U.S. appeals court is set to hear arguments to reinstate over 500 lawsuits against Kenvue (KVUE) concerning an alleged link between Tylenol and autism, following a lower court's dismissal in 2024. Plaintiffs are leveraging a September press conference where former President Donald Trump and health officials publicly promoted these claims, despite researchers and Kenvue asserting no firm scientific evidence supports such a link. This legal development introduces renewed uncertainty regarding Kenvue's product liability.

This legal challenge unfolds amidst Kimberly-Clark's (KMB) planned $40 billion acquisition of Kenvue, slated for next year. Notably, merger documents filed with the SEC explicitly state that any "condition, development or occurrence" related to Tylenol/autism allegations would not constitute grounds for Kimberly-Clark to terminate the agreement. This clause suggests KMB has already factored in potential litigation risks, mitigating immediate deal uncertainty.

Kenvue is also defending a separate lawsuit by the Texas Attorney General alleging concealed risks, though a recent ruling declined to block Kenvue's scheduled $398 million shareholder dividend or modify its marketing. This indicates Kenvue's ability to maintain capital returns despite ongoing legal pressures. The negative per-ticker sentiment for KVUE (-0.2) reflects the litigation overhang, while KMB remains neutral (0.0).

Key Decisions for Investors

• Monitor the appeals court ruling on Kenvue's Tylenol lawsuits, as a reinstatement could increase long-term legal costs and reputational risk for KVUE, despite the existing acquisition agreement.
• Assess Kimberly-Clark's (KMB) due diligence and the explicit merger clause regarding Tylenol litigation, which suggests these risks are already priced into the $40 billion acquisition, potentially limiting direct deal-related downside from this specific legal event.
• Evaluate broader product liability exposures within consumer health portfolios, as this case underscores the potential for politically amplified litigation against established brands, even without clear scientific consensus.